Yanghe Biomedicine Industry Fund

The fund targets early-stage companies in biomedicine, medical devices, diagnostics and agricultural biotechnology, deploying across seed, start-up and growth stages from its base in Guangzhou. This dual focus on human health and agri-food biotech distinguishes it from pure-play life-science investors in China. No portfolio companies have been publicly disclosed in English-language records.

Specific principals and investment committee members have not been identified through public record or English-language media. The fund's ownership structure, corporate affiliations and decision-making hierarchy remain undisclosed outside of China's domestic regulatory or corporate filings. No named investment leads are currently available.

The naming convention suggests a possible corporate affiliation, but no direct ownership link to Jiangsu Yanghe Distillery Co. Ltd. or any Yanghe-branded entity has been confirmed in public record. The fund's Guangzhou headquarters and biomedical mandate do not obviously align with the Suqian-based distillery group's known investment activities. The relationship, if any, remains unverified.

Given its Guangzhou location within the Pearl River Delta's biomedical corridor, the fund likely sources through academic tech-transfer offices, provincial government industrial development funds and local incubators. The convergence of healthcare and agriculture biotech mandates suggests additional sourcing channels through China's agricultural research institutes and food-science clusters. No formal co-investment partnerships or sourcing networks have been disclosed.

The fund's capital structure and LP base have not been publicly disclosed. As a private equity vehicle with an asset-manager designation, it may raise capital from institutional investors, high-net-worth individuals or a corporate parent, but no fundraising details or regulatory filings are available in English-language records.